Transplant rejection can be classified as hyperacute, acute, or chronic. Hyperacute rejection is usually caused by specific antibodies against the graft and occurs within minutes or hours after grafting. Acute rejection occurs days or weeks after transplantation and can be caused by specific lymphocytes in the recipient that recognize HLA antigens in the tissue or organ grafted. Finally, chronic rejection usually occurs months or years after organ or tissue transplantation. Various mechanisms involving chronic inflammation, humoral, and cellular immune reactions play an essential role in the immunopathogenesis of chronic rejection.
The etiology of chronic rejection is incompletely understood. Glinton et al. reported that a vital determinant of the complication of chronic solid organ allografts is by a vascular disease component of the transplanted graft. Their review, however, focused on cardiac transplantation only. In cardiac allograft vasculopathy, histologic evidence suggests that accumulation and activation of phagocytes can be a contributing factor. Phagocytic cells such as macrophages, monocytes, and immature dendritic cell subsets are found in this type of chronic cardiac transplant rejection. Furthermore, myeloid phagocytes crosstalk with B and T lymphocytes while also signaling and activating vascular smooth muscle cells and fibroblasts, and these can cause fibrous intimal thickening. Chronic renal allograft rejection has been labeled as interstitial fibrosis and tubular atrophy to help reflect the underlying histology and etiology. Chronic rejection is now cited as the leading cause of graft rejection.
The overall incidence and prevalence of chronic allograft nephropathy (CAN) in biopsies of renal allograft tissues depends on the timing and the indication of such graft biopsies. In protocol biopsies, in the first year post-transplantation, it has been reported that the prevalence can be as high as 94% (Grade I) and up to 100% after 10 years.
In the United States, mortality in patients on chronic hemodialysis is significantly higher in winter months than in the summer. It is unknown whether a seasonal difference exists, however, for mortality or graft failure among kidney transplant recipients. One report showed that there was a significant annual variation of deaths due to graft failures.
Chronic allograft rejection can be caused by antibody-dependent complement activation lesions as well as cell arteritis leading to the development of interstitial fibrosis/tubular atrophy (IF/TA). This injury can appear early after transplantation. At 1-year post-transplant, greater than 81% of the kidneys have minimal lesions of IF/TA that tend to progress over time; these lesions affect greater than 50% of transplanted kidneys with severe lesions at 5 years.
The 2011 Banff meeting focused on diagnostic criteria for late-antibody mediated rejection. In this review, there was the recognition of CD4-negative antibody-mediated rejection, in which endothelial activation and NK cells were suggested as the primary causes of chronic reaction. Other proposed pathophysiologic mechanisms include:
The main histological finding in biopsies of rejected organs is arteriosclerosis that causes a progressive luminal narrowing of graft vessels. This is typically referred to as a vasculopathy or graft vascular disease. This entity is often accompanied by graft tissue (parenchymal) fibrosis. For example, livers with chronic rejection show a decreased number of bile ducts on biopsy and obliteration of small arteries. Correspondingly, lung rejection is characterized by bronchiolitis obliterans.
Individuals presenting with chronic transplant rejection will have had a previous history of an organ or tissue transplantation (for example, kidney, liver, and lung) for any of many chronic medical conditions. The symptoms and signs of rejections depend on the organ transplanted; for instance, a chronic kidney rejection causes fatigue, fever, flu-like symptoms, anuria or decreased urine output, generalized edema, and pain or tenderness at the site of transplantation. Other signs and symptoms of organ rejection can include:
Various laboratory tests can be ordered to test for chronic rejection. These may include the following:
In renal transplantation, urinary samples can prove useful to determine rejection. Tubular epithelial cells, casts, oxalate crystals (sand-glass shaped), dirty background, increasing erythrocyturia, mixed cell clusters, lymphocytes, and mitoses all may be observed.
"Owl-eye" cells milk-glass nuclei, sometimes with eosinophilic condensation, typically characterize cytologic examination of the voided urine in CMV infection. Serological tests can further help in differentiating CMV-infection from allograft rejection.
The treatment of organ rejection depends on the type of injury and underlying etiology. In chronic kidney rejection, complications including arterial hypertension, pulmonary edema, and uremia should be managed through various therapeutic options, including but not limited to hemodialysis, hemofiltration, and the use of diuretics.
As a general statement, most infectious causes should be treated with specific, directed antimicrobials.
In diabetic nephropathy, the albumin to creatinine ratio can be used to guide therapy. If this ratio is greater than 3, inhibition of the renin-angiotensin system is recommended with an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB). This therapy should be pursued even in the setting of normal blood pressure to help protect the donor's kidney.
Tight glucose control is recommended in the setting of hyperglycemia. In type 1 diabetes mellitus, therapy is typically accomplished with insulin, and in non-insulin dependent diabetes mellitus, therapy is usually with a biguanide or sulfonylurea.
In end-stage rejection, there may be a consideration for re-transplantation of the organ or tissues.
The differential diagnosis for chronic rejection is broad but includes acute rejection, infection (CMV), medication toxicity (immunosuppressants), posttransplant lymphoproliferative disease, or technical problems with vascular or structural anastomotic complications.
The FTY720 (Fingolimod) is a novel immunosuppressive agent that has been investigated in the last few decades. FTY is highly effective in prolonging graft survival in preclinical models of transplantation and multiple sclerosis. FTY720 is an immunomodulator. Its mode of action differs completely from traditional immunosuppressants. It is a new class of drugs named sphingosine 1-phosphate receptor (S1P-R) modulators. In laboratory animals S1P receptor activation with fingolimod activates anti-inflammatory and anti-apoptotic pathways, leading to improved myocardial salvage by reducing cardiac fibrosis.
ASP0028, an S1P1/S1P5-selective agonist, with comparable efficacy to FTY720 and wider safety margins than FTY720 showed the efficacy and safety when it was co-administered with suboptimal-dose of tacrolimus in a monkey renal transplantation model. ASP0028 administration remarkably reduced peripheral lymphocytes, including subsets of CD4+/ or CD8+/naive and memory cells, CD4+/Treg cells, and B cells, but not CD4+/ or CD8+/effector memory cells and natural killer (NK) cells. These data support the finding that ASP0028 and tacrolimus prolong renal allograft survival in primates.
Banff grading system is a classification of the severity of chronic renal allograft nephropathy. This was originally implemented in 1997 and updated subsequently in 2005, 2007, 2009, 2013, and 2017. This schema grades disease severity according to interstitial fibrosis, atrophy and loss of tubules (IF/TA):
As many as one-third of cadaveric kidney transplant recipients suffer graft loss within 5 years of transplantation.
Unfortunately, changes in immunotherapy have proven to be mostly ineffective in changing the prognosis for patients with established chronic allograft nephropathy.
Prevention, early diagnosis, management of both co-morbidity and complications of chronic kidney disease can improve the survival of patients with transplant failure.
The success of organ transplantation depends on the use of immunosuppressive drugs to control the alloimmune response. The most frequent drugs used for kidney transplantation include a cocktail of 3 medications including a drug that inhibits T-cell activation (cyclosporin, tacrolimus, or sirolimus), an antiproliferative (6-mercaptopurine, or mycophenolic acid) and an anti-inflammatory agent (corticosteroids).
Chronic organ rejection can be associated with a high mortality rate and may result in various complications, including kidney failure, liver failure, chronic pulmonary disease, pancreatic insufficiency, arteriosclerosis, and blood dyscrasias.
Other complications include CMV infection and infectious diseases caused by bacterial, viral, fungal, protozoal or mixed. Excessive immunosuppression can cause the emergence of BK polyomavirus resulting in BK nephropathy and may account for one to ten percent of allograft failure.
A late complication of renal transplantation is the recurrence of the original disease (diabetic nephropathy).
Development of malignancy is a late complication of chronic organ rejection. For example, the incidence of lymphoma is approximately 40 times greater in transplant recipients than in the general population. Other tumors that may be observed include skin cancer, Kaposi sarcoma and lymphoma due to Epstein-Barr virus activation.
It is mandatory for patients to be compliant with immunosuppressive drugs to avoid organ rejection and improve the quality of life. Similarly, patients must also comply with the treatment of any underlying comorbidities.
An interprofessional team educates and manage the patient with chronic rejection. Since this condition is life-threatening, the health care providers should advise the patient fully about all other treatment options, psychological support, and in extreme circumstances, consideration for an organ or tissue re-transplantation.
|||Glinton K,DeBerge M,Yeap XY,Zhang J,Forbess J,Luo X,Thorp EB, Acute and chronic phagocyte determinants of cardiac allograft vasculopathy. Seminars in immunopathology. 2018 Nov [PubMed PMID: 30141073]|
|||Astor BC,Melamed ML,Mandelbrot DA,Djamali A, Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. Transplant international : official journal of the European Society for Organ Transplantation. 2018 Mar [PubMed PMID: 28871657]|
|||Solez K,Colvin RB,Racusen LC,Sis B,Halloran PF,Birk PE,Campbell PM,Cascalho M,Collins AB,Demetris AJ,Drachenberg CB,Gibson IW,Grimm PC,Haas M,Lerut E,Liapis H,Mannon RB,Marcus PB,Mengel M,Mihatsch MJ,Nankivell BJ,Nickeleit V,Papadimitriou JC,Platt JL,Randhawa P,Roberts I,Salinas-Madriga L,Salomon DR,Seron D,Sheaff M,Weening JJ, Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2007 Mar [PubMed PMID: 17352710]|
|||Mengel M,Sis B,Haas M,Colvin RB,Halloran PF,Racusen LC,Solez K,Cendales L,Demetris AJ,Drachenberg CB,Farver CF,Rodriguez ER,Wallace WD,Glotz D, Banff 2011 Meeting report: new concepts in antibody-mediated rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012 Mar [PubMed PMID: 22300494]|
|||Kloc M,Ghobrial RM, Chronic allograft rejection: A significant hurdle to transplant success. Burns [PubMed PMID: 27574640]|
|||Winkelmann M,Grabensee B,Pfitzer P, Differential diagnosis of acute allograft rejection and CMV-infection in renal transplantation by urinary cytology. Pathology, research and practice. 1985 Aug [PubMed PMID: 2997762]|
|||Dun H,Song L,Ma A,Hu Y,Zeng L,Bai J,Zhang G,Zhang L,Koide K,Okada Y,Hanaoka K,Yamamoto R,Hirose J,Morokata T,Daloze P,Chen H, ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model. Transplant immunology. 2017 Feb [PubMed PMID: 28077266]|
|||Budde K,Schütz M,Glander P,Peters H,Waiser J,Liefeldt L,Neumayer HH,Böhler T, FTY720 (fingolimod) in renal transplantation. Clinical transplantation. 2006 [PubMed PMID: 17100697]|
|||Ahmed N,Linardi D,Muhammad N,Chiamulera C,Fumagalli G,Biagio LS,Gebrie MA,Aslam M,Luciani GB,Faggian G,Rungatscher A, Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation. Frontiers in pharmacology. 2017 [PubMed PMID: 28966593]|